.png)
The DOJ has finally acted on President Trump’s December 2025 Executive Order, but the April 22, 2026 Attorney General Order creates a narrow, bifurcated framework that affects certain medical operators while leaving the broader marijuana industry and many core criminal justice concerns largely untouched.
To be clear, this is a regulatory shift. It is not systemic reform.
WHAT HAPPENED
The DOJ is rolling out marijuana rescheduling from Schedule I to Schedule III in two distinct phases:
Phase 1: Immediate Rescheduling of Marijuana by Order
The Attorney General issued a final order (effective April 22, 2026) placing the following marijuana-derived products into Schedule III:
- FDA-approved drugs containing marijuana and marijuana extracts
- State-legal medical marijuana and extracts
- Naturally derived delta-9 THC within the above two categories
This order is effective immediately, issued pursuant to the Attorney General’s authority to act in compliance with the U.S.’s international treaty obligations.
At the same time, any marijuana outside these categories remains in Schedule I, including adult-use products and unlicensed activity.
Phase 2: Broader Rescheduling of Marijuana Still to Come
Beginning June 29, 2026, DOJ and DEA will conduct expedited administrative hearings to determine whether all marijuana should be rescheduled to Schedule III.
This Phase 2 process replaces the prior rule-making that began under the Biden Administration (but ultimately stalled), signaling a new, accelerated rescheduling effort.
THE “BAD”: WHAT THIS DOES NOT FIX
For many industry participants, the practical reality is still challenging:
No Criminal Justice Relief
From a criminal justice perspective, this Order is narrow and incomplete:
- No retroactive decriminalization
- No automatic expungement or presidential pardons
- No sentencing relief or support for marijuana prisoners
- No end to marijuana-related arrests tied to Schedule I activity or the collateral consequences that follow such arrests
In short: the conduct that has historically driven criminal exposure largely remains criminal, unless it falls squarely within the newly defined medical lane of Schedule III.
Immigration Risks Persist
- Any marijuana-related activity remains federally prohibited
- Schedule III does not protect a non-citizen or immigrant that participates in a marijuana-related business or activity from deportation, inadmissibility, or being barred from citizenship.
- Non-citizens involved in marijuana operations remain at risk of removal or inadmissibility
Adult-Use Marijuana Remains Federally Illegal
- Still classified as a Schedule I substance
- Still subject to criminal, civil, and regulatory enforcement
- Still excluded from 280E relief
No Protection for Mixed Adult-Use and Medical Operators
Businesses operating both medical and adult-use licenses may face:
- Complex tax allocation issues
- Continued exposure on non-medical revenue streams
Federal-State Conflict Persists
- The Order does not harmonize federal law with state adult-use programs.
- Many operators remain caught between state legality and federal prohibition, with ongoing compliance and enforcement risk.
THE “GOOD”
For those operating in state-legal medical marijuana systems, the Order delivers real, near-term advantages:
Long Overdue Recognition of Medicinal Benefits of Marijuana
- For decades, the federal government stigmatized marijuana and its users, effectively gaslighting millions of medical patients into thinking they were doing something wrong when they were simply treating their ailments with this plant.
- By placing marijuana into Schedule III, the federal government is finally acknowledging (albeit implicitly) that marijuana is medicine, validating medical marijuana patients and their lived experiences.
Pathway to 280E Relief
Because § 280E applies only to Schedule I and II substances:
- Qualifying medical operators may no longer be subject to 280E disallowance, subject to IRS guidance
- DOJ is encouraging retroactive relief, subject to IRS guidance
Expanded Research Opportunities
Schedule I research barriers are lifted for rescheduled products:
- Researchers may now access state-licensed marijuana for studies
- However, research remains subject to the Medical Marijuana and Cannabidiol Research Expansion Act, which still imposes regulatory controls
Streamlined Federal Registration
Phase 1 introduces an expedited DEA registration pathway for state-licensed medical marijuana operators:
- Applicants may submit existing state licenses and credentials as conclusive evidence of state-law authorization
- The DEA is directed to grant registration unless doing so would conflict with public interest factors under 21 U.S.C. § 823 or treaty obligations
- The framework effectively incorporates state medical programs into the federal system, while preserving federal oversight
Practically, this means state licensure becomes the gateway to federal compliance, but also that loss or suspension of a state license may jeopardize federal authorization.
THE “MIXED BAG”: WHERE YOU NEED TO BE STRATEGIC
A Split Industry Is Now Formalized
This Order creates a two-tier system:
- Federally recognized (medical, regulated, compliant)
- Federally prohibited (adult-use and everything else)
That divide has real consequences for:
- Tax planning
- Corporate structuring
- Investment strategy
- Compliance risk
Pharmaceutical Model Is Taking Hold
Federal acceptance is being channeled through:
- DEA registration
- Prescription frameworks
- Record-keeping, quotas, and controls tied to international treaty obligations
This is not full normalization, but it is meaningful federal integration of medical marijuana.
Research Is Easier, but Not Unrestricted
While Schedule I barriers are removed for covered products:
- Research still operates within federal licensing and statutory constraints
- The Medical Marijuana and Cannabidiol Research Expansion Act continues to govern access and protocols
WHAT THIS MEANS FOR INDUSTRY PARTICIPANTS
Medical Operators
- Immediate opportunity for federal alignment and potential tax relief
- Should evaluate DEA registration and compliance obligations promptly
Mixed Medical / Adult-Use Businesses
- Need careful segregation of operations
- Likely partial 280E exposure
- Heightened importance of entity and accounting structure
- Watch carefully for changes to federal enforcement priorities of criminal law
Adult-Use Operators
- No immediate benefit
- Continued federal illegality and 280E exposure
- Should prepare strategically for Phase 2 developments
- Watch carefully for changes to federal enforcement priorities of criminal law
Bottom Line
While this is a targeted step forward for federal marijuana policy, particularly for medical operators, it is not a comprehensive solution for the industry at large.
- It creates real opportunities for a segment of the industry
- It signals federal willingness to evolve
- It leaves key criminal justice and adult-use issues unresolved
- And it requires careful, strategic planning across all business models
RLG CAN HELP
We are actively advising clients across medical, adult-use, and mixed-license structures and are available to discuss tailored strategies in light of these developments.
If you have questions about how the DOJ’s rescheduling announcement and Order impact your business, operations, or risk profile, Rudick Law Group is available to assist with:
- Corporate formation and restructuring
- DEA registrations
- Investor relations strategy and support
- Risk profile assessment
- Operational best practices
- Optimization and efficiencies across your business
The information above reflects what is known at this time based on the DOJ’s announcement and the Attorney General’s Order. We expect additional guidance and developments as federal agencies continue to implement this framework. Please stay tuned for updates!
The federal government just drew a hard line between medical and adult-use cannabis. Where your business falls determines your tax exposure, your compliance obligations, and your next steps.
.webp)
